SODIUM ACETYLATED HYALURONATE
What is SODIUM ACETYLATED HYALURONATE (CAS N/A) in cosmetics and what are its global regulatory limits?
SODIUM ACETYLATED HYALURONATE (CAS No. N/A) is a verified cosmetic ingredient primarily functioning as Humectant in topical formulations. Regulated under KR MFDS (Unregulated) and EU 1223/2009 CosIng (Unregulated) statutory frameworks, it is typically formulated at 0.1–5.0% within an optimal stability window of pH 4.5–7.5.
7-Track Official Regulatory Label Names Matrix
Primary Statutory Gazette Only · Zero Machine Translation| Jurisdiction Track | Official Statutory Label Name | One-Click Copy |
|---|---|---|
| 1. Korea (MFDS Standard Name) | SODIUM ACETYLATED HYALURONATE (KR MFDS Registered) | |
| 2. Korea Former Nomenclature History | — | — |
| 3. European Union (EU CosIng Glossary) | SODIUM ACETYLATED HYALURONATE | |
| 4. United States (US PCPC / MoCRA INCI) | SODIUM ACETYLATED HYALURONATE | |
| 5. US FDA OTC Monograph Active Name | — (Cosmetic Inactive / Non-OTC) | — |
| 6. China (NMPA IECIC Standard Name) | 乙酰化透明质酸钠 | |
| 7. Japan (JCIA Standard / MHLW Quasi-Drug) | アセチルヒアルロン酸Ｎａ · [QD: アセチル化ヒアルロン酸ナトリウム] |
Layer 1 — Statutory Regulatory Limits Across 6 Regions
| Region | Status | Max Limit | Conditions & Statutory Source |
|---|---|---|---|
| Korea (MFDS) | Unregulated | GMP | Listed in official cosmetic inventory |
| Europe (EU) | Unregulated | GMP | Listed in official cosmetic inventory |
| United States (FDA) | Unregulated | GMP | Listed in official cosmetic inventory |
| China (NMPA) | Listed / Allowed | GMP | IECIC Entry #7772 |
| Japan (MHLW) | Unregulated | GMP | Listed in official cosmetic inventory |
| ASEAN (ACD) | Unregulated | GMP | Listed in official cosmetic inventory |
Layer 2 — Toxicological & Historical Safe Use Concentrations (CIR / SCCS / CN IECIC / IFRA)
“EU SCCS Safe Opinion Limit” is the toxicological safe threshold (MoS≥100), whereas “US CIR Reported Max Use” and “CN IECIC Historical Max Use” represent historical maximum concentrations in commercial products.
| Assessment Basis | Application Scope | Concentration Range | Verdict & Dossier Reference |
|---|---|---|---|
| CN IECIC Historical Max Use | leave_on | ≤ 1% | Safe (MoS≥100)NMPA IECIC (2025) Entry 07780 (2025) |
| CN IECIC Historical Max Use | rinse_off | ≤ 0.5% | Safe (MoS≥100)NMPA IECIC (2025) Entry 07780 (2025) |
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Outside pH 4.5–7.5, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Thermally stable up to 70°C during standard emulsification.
Cellular & Molecular Target Mechanism Flow
Academic & Toxicological Synthesis
Tier 2 SynthesisSynthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.
Linked Peer-Reviewed Literature (NIH PubMed) (1)
The anti-wrinkles properties of sodium acetylated hyaluronate [PMID: 34708918 · 2022]
Intrinsic aging promotes wrinkles formation by an imbalance between matrix synthesis/degradation in favor of degradation. This is accelerated by the exposome leading to overproduction of protease and fewer remodeling. Protecting the integrity of extracellular matrix appears as the most efficient anti-aging solution. We developed a grafted HA specifically designed to get anti-aging property due to a specific molecular weight and acetylation degree. A transcriptomic analysis was performed on fibroblasts, followed by a measurement of MMP secretion and subsequent effect on collagen degradation. MMP expression in skin explants concerned by chronobiological and extrinsic aging was analyzed by immunostaining. A clinical study was conducted on volunteers presenting wrinkles on face to evaluate flash reduction of wrinkles after 6 h of application by profilometry and anti-aging efficacy after 2 months by VISIA ® CR2.3. Transcriptomic analysis evidenced an inhibition of MMP gene expression with acetylated HA, confirmed by an inhibition of MMPs release by fibroblasts, and a protection of type I collagen against degradation. We confirmed the reduction of MMPs in mature skin and in skin explants exposed to UV and urban dust. We demonstrated during clinical studies the flash reduction effect of acetylated HA on crow's feet wrinkles and a filling of nasogenian areas 6 h after application, and a wrinkles number reduction on nasogenian area up to 2 months of application. We developed a new grafted HA owing protective properties against ECM degradation induced by chronobiological and extrinsic aging, leading to a significant and efficient anti-wrinkles effect.
Frequently Asked Questions (AEO Position 0)
- Q1. What are the official 7-track regulatory label names for SODIUM ACETYLATED HYALURONATE?
- Standard label names are US PCPC INCI: 'SODIUM ACETYLATED HYALURONATE', EU CosIng: 'SODIUM ACETYLATED HYALURONATE', KR MFDS: 'SODIUM ACETYLATED HYALURONATE (KR MFDS Registered)', CN NMPA IECIC: '乙酰化透明质酸钠', and JP JCIA: 'アセチルヒアルロン酸Ｎａ'.
- Q2. Is SODIUM ACETYLATED HYALURONATE restricted or permitted in EU, US, KR, CN, and JP cosmetics?
- Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.
- Q3. What is the typical formulation concentration and optimal pH window for SODIUM ACETYLATED HYALURONATE?
- Formulate within pH 4.5–7.5 and max process temperature ≤70°C.
- Q4. What are the known formulation incompatibilities and synergy pairings for SODIUM ACETYLATED HYALURONATE?
- Recommended synergy pairings include Panthenol, Ceramide NP, Hydrolyzed Sponge. Key incompatibilities to avoid: Extreme pH or strong oxidizing agents.